Simultaneous blockade of angiotensin receptors and enhancement of natriuretic peptides 3 (NP) by the first-in-class angiotensin receptor neprilysin (NEP) inhibitor sacubitril/valsartan 4 constitutes an effective approach to treating heart failure. This study examined the effects of 5 sacubitril/valsartan (225 and 675mg/day) vs. placebo, sacubitril (360mg/day), valsartan 6 (900mg/day), and benazepril (5mg/day) on the dynamics of the renin-angiotensin- 7 aldosterone system (RAAS) and the NP system in dogs. Beagle dogs (n=18) were fed a 8 low-salt diet (0.05% Na) for 15 days to model RAAS activation observed in clinical heart 9 failure. Drugs were administered once daily during the last 10 days, while the effects on the 10 RAAS and NPs were assessed on days 1, 5, and 10. Steady-state pharmacokinetics of the 11 test agents were evaluated on day 5. Compared with placebo, sacubitril/valsartan (675mg) 12 substantially increased cGMP circulating levels, while benazepril and valsartan showed no 13 effect. Additionally, sacubitril/valsartan (675mg) and valsartan significantly increased 14 plasma renin activity, angiotensin I and angiotensin II concentrations. Finally, 15 sacubitril/valsartan (both doses), and valsartan significantly decreased plasma aldosterone 16 vs. placebo. Systemic exposure to valsartan following sacubitril/valsartan 675mg 17 administration was similar to that observed with valsartan 900mg administration alone. 18 Sacubitril/valsartan favorably modulates the dynamics of the renin and NP cascades 19 through complementary NEP and RAAS inhibition.
SVH, VAL, and BNZ), DAY (D1, D5, and D10) and the two-way interaction TRT by DAY. 193 ANIMAL (1 to 18) was included as a random effect in the model. 194 Finally, in order to leverage all available pharmacodynamic information and derive 195 meaningful and robust statistical comparisons, plasma biomarker data (both time courses 196 and TWAs) from days 1, 5, and 10 were pooled for each treatment and analyzed by the 197 RRMANOVA approach. All calculations were done using SAS ® Version 9.2 by applying 198 univariate analysis for calculation of summary statistics. SAS ® procedure was applied to 199 execute the analyses of variance. All tests were performed two-sided with a level of 200 significance α pre-defined at 0.05. 
Effect on plasma cGMP
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The typical baseline value for cGMP across treatment groups was ca. 15 pmol/mL.
213
RRMANOVA results showed significant increases in cGMP circulating levels within all In addition, differences to PBO were found to be statistically significant 262 for SVH, SVL and VAL, but not significant for BNZ ( Figure 6 , Panel C Because of the small study size, the statistical significance of certain findings was 365 hampered by low statistical power. This is illustrated by the non-significance of the inhibitory Figure 6 
